CORRECTION

Open Access



Correction: A review and recommendations for oral chaperone therapy in adult patients with Fabry disease

Michał Nowicki^{1*}, Stanisława Bazan-Socha², Beata Błażejewska-Hyżorek³, Mariusz M. Kłopotowski⁴, Monika Komar⁵, Mariusz A. Kusztal⁶, Tomasz Liberek⁷, Jolanta Małyszko⁸, Katarzyna Mizia-Stec⁹, Zofia Oko-Sarnowska¹⁰, Krzysztof Pawlaczyk¹¹, Piotr Podolec⁵ and Jarosław Sławek¹² on behalf of the Polish Fabry Disease Collaborative Group

Correction: Orphanet J Rare Dis (2024) 19:16 https://doi.org/10.1186/s13023-024-03028-w

Following publication of the original article [1], we have been notified that there was a mistake in the body text of the article.

It is now:

The original article can be found online at https://doi.org/10.1186/s13023-024-03028-w.

*Correspondence: Michał Nowicki

nefro@wp.pl

¹ Department of Nephrology, Hypertension and Kidney Transplantation, Central University Hospital, Medical University of Lodz, Pomorska 251, 92-213 Lodz, Poland

² Department of Internal Medicine, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland

³ 2Nd Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland

⁴ Department of Interventional Cardiology and Angiology, Cardinal Wyszynski National Institute of Cardiology-National Research Institute, Warsaw, Poland

⁵ Department of Cardiac and Vascular Diseases, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland

⁶ Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wroclaw, Poland

⁷ Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gdańsk, Gdańsk, Poland

⁸ Department of Nephrology, Dialysis and Internal Medicine, Medical

University of Warsaw, Warsaw, Poland

⁹ First Department of Cardiology, Faculty of Medicine in Katowice, Medical University of Silesia, Katowice, Poland

Polish experience with migalastat therapy

At the end of December 2024, 32 FD patients are treated with migalastat in Poland, and none was discontinued.

It should be:

Polish experience with migalastat therapy

At the end of December 2023, 32 FD patients are treated with migalastat in Poland, and none was discontinued.

Published online: 28 March 2024

Reference

1. Nowicki, et al. A review and recommendations for oral chaperone therapy in adult patients with Fabry disease. Orphanet J Rare Dis. 2024;19:16. https://doi.org/10.1186/s13023-024-03028-w.

¹¹ Department of Nephrology, Transplantology and Internal Medicine, Poznań University of Medical Sciences, Poznan, Poland

¹² Department of Neurological-Psychiatric Nursing, Department

of Neurology and Stroke, Faculty of Health Sciences, St. Adalbert Hospital, Medical University of Gdansk, Gdańsk, Poland



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

¹⁰ 1St Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland